JP2009526532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526532A5 JP2009526532A5 JP2008554674A JP2008554674A JP2009526532A5 JP 2009526532 A5 JP2009526532 A5 JP 2009526532A5 JP 2008554674 A JP2008554674 A JP 2008554674A JP 2008554674 A JP2008554674 A JP 2008554674A JP 2009526532 A5 JP2009526532 A5 JP 2009526532A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- extension box
- nucleotide sequence
- box
- acid according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 225
- 108020004707 nucleic acids Proteins 0.000 claims description 203
- 102000039446 nucleic acids Human genes 0.000 claims description 203
- 239000002773 nucleotide Substances 0.000 claims description 193
- 125000003729 nucleotide group Chemical group 0.000 claims description 191
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 65
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 65
- 102000019034 Chemokines Human genes 0.000 claims description 46
- 108010012236 Chemokines Proteins 0.000 claims description 46
- 239000000523 sample Substances 0.000 claims description 39
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims description 25
- 102000046768 human CCL2 Human genes 0.000 claims description 25
- 238000001514 detection method Methods 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 239000002556 chemokine receptor agonist Substances 0.000 claims description 20
- 239000002559 chemokine receptor antagonist Substances 0.000 claims description 19
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims description 14
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 14
- 101710155833 C-C motif chemokine 8 Proteins 0.000 claims description 14
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 14
- 101710139422 Eotaxin Proteins 0.000 claims description 14
- 102100023688 Eotaxin Human genes 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 238000009396 hybridization Methods 0.000 claims description 14
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims description 14
- 238000012986 modification Methods 0.000 claims description 14
- 230000004048 modification Effects 0.000 claims description 14
- 102100024502 Ceramide glucosyltransferase Human genes 0.000 claims description 7
- 101000981050 Homo sapiens Ceramide glucosyltransferase Proteins 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 101000897464 Mus musculus C-C motif chemokine 2 Proteins 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010048832 Colon adenoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000002927 Hamartoma Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 208000004362 Penile Induration Diseases 0.000 claims description 2
- 208000020758 Peyronie disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010038540 Renal tubular necrosis Diseases 0.000 claims description 2
- 206010038848 Retinal detachment Diseases 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000003143 atherosclerotic effect Effects 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 201000002491 encephalomyelitis Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000002674 obstructive nephropathy Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims description 2
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 claims description 2
- 230000004264 retinal detachment Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000030961 allergic reaction Diseases 0.000 claims 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 235000020289 caffè mocha Nutrition 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 101000897479 Bos taurus C-C motif chemokine 2 Proteins 0.000 description 8
- 241000282465 Canis Species 0.000 description 8
- 241000282693 Cercopithecidae Species 0.000 description 8
- 101000897485 Equus caballus C-C motif chemokine 2 Proteins 0.000 description 8
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 8
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 8
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 102000043805 human CCL8 Human genes 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06002935.2 | 2006-02-14 | ||
| EP06002935 | 2006-02-14 | ||
| EP06024202 | 2006-11-22 | ||
| EP06024202.1 | 2006-11-22 | ||
| PCT/EP2007/001294 WO2007093409A2 (en) | 2006-02-14 | 2007-02-14 | Mcp-i binding nucleic acids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009526532A JP2009526532A (ja) | 2009-07-23 |
| JP2009526532A5 true JP2009526532A5 (enExample) | 2010-04-08 |
| JP5537812B2 JP5537812B2 (ja) | 2014-07-02 |
Family
ID=38198593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008554674A Active JP5537812B2 (ja) | 2006-02-14 | 2007-02-14 | Ｍｃｐ−１に結合する核酸 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8193159B2 (enExample) |
| EP (3) | EP2365080B1 (enExample) |
| JP (1) | JP5537812B2 (enExample) |
| KR (2) | KR101572893B1 (enExample) |
| CN (2) | CN103275984A (enExample) |
| AT (1) | ATE510014T1 (enExample) |
| AU (1) | AU2007214668B2 (enExample) |
| BR (1) | BRPI0707842B8 (enExample) |
| CA (1) | CA2638847C (enExample) |
| DK (1) | DK2135949T3 (enExample) |
| ES (1) | ES2397803T3 (enExample) |
| MX (2) | MX351107B (enExample) |
| PL (1) | PL2135949T3 (enExample) |
| PT (1) | PT2135949E (enExample) |
| RU (1) | RU2518330C2 (enExample) |
| WO (1) | WO2007093409A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2638847C (en) | 2006-02-14 | 2016-08-09 | Noxxon Pharma Ag | Mcp-1 binding nucleic acids |
| US8367629B2 (en) * | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| WO2009068318A1 (en) * | 2007-11-30 | 2009-06-04 | Noxxon Pharma Ag | Mcp-i binding nucleic acids and use thereof |
| US8710021B2 (en) * | 2008-06-11 | 2014-04-29 | Bionucleon S.R.L. | Inhibition of HRP-3 using modified oligonucleotides |
| WO2010070394A1 (en) * | 2008-12-17 | 2010-06-24 | Universite Pierre Et Marie Curie-Paris Vi | Modulators of the cx3cr1 receptor and therapeutic uses thereof |
| WO2012025251A1 (en) * | 2010-08-27 | 2012-03-01 | Noxxon Pharma Ag | Nucleic acids for treatment of chronic complications of diabetes |
| US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| JP2017502075A (ja) | 2013-11-04 | 2017-01-19 | ノクソン ファーマ エージー | 腎障害治療の手段および方法 |
| WO2021178923A1 (en) | 2020-03-06 | 2021-09-10 | Drinksavvy, Inc. | Devices and methods for detecting a target analyte of interest |
| WO2023154452A1 (en) | 2022-02-11 | 2023-08-17 | Waypoint Bio, Inc. | Cellular staining probes for analyte detection |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US6670321B1 (en) * | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| ES2346640T4 (es) * | 2001-10-26 | 2011-04-26 | Noxxon Pharma Ag | Ácido l-nucleico modificado. |
| EP1386972A1 (en) | 2002-08-01 | 2004-02-04 | Noxxon Pharma AG | Method and apparatus for designing a nucleic acid having a desired property |
| AU2003251681A1 (en) * | 2002-08-01 | 2004-02-23 | Noxxon Pharma Ag | Ghrelin binding nucleic acids |
| US20090281296A1 (en) | 2004-02-09 | 2009-11-12 | Supramol Parenteral Colloid Gmbh | Process for the production of conjugates from polysaccharides and polynucelotides |
| US20060030535A1 (en) * | 2004-03-05 | 2006-02-09 | Healy Judith M | Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics |
| WO2005108431A1 (en) * | 2004-05-04 | 2005-11-17 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of ocular neovascularization |
| US8367629B2 (en) * | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
| CA2638847C (en) | 2006-02-14 | 2016-08-09 | Noxxon Pharma Ag | Mcp-1 binding nucleic acids |
| KR101589442B1 (ko) * | 2007-08-06 | 2016-02-01 | 녹손 파르마 아게 | 에스디에프-1 결합형 핵산 및 이의 용도 |
| WO2009068318A1 (en) | 2007-11-30 | 2009-06-04 | Noxxon Pharma Ag | Mcp-i binding nucleic acids and use thereof |
-
2007
- 2007-02-14 CA CA2638847A patent/CA2638847C/en active Active
- 2007-02-14 BR BRPI0707842A patent/BRPI0707842B8/pt active IP Right Grant
- 2007-02-14 CN CN2013101587615A patent/CN103275984A/zh active Pending
- 2007-02-14 ES ES09012826T patent/ES2397803T3/es active Active
- 2007-02-14 EP EP11001720.9A patent/EP2365080B1/en not_active Not-in-force
- 2007-02-14 MX MX2016003546A patent/MX351107B/es unknown
- 2007-02-14 JP JP2008554674A patent/JP5537812B2/ja active Active
- 2007-02-14 DK DK09012826.5T patent/DK2135949T3/da active
- 2007-02-14 EP EP09012826A patent/EP2135949B1/en active Active
- 2007-02-14 RU RU2008136907/10A patent/RU2518330C2/ru active IP Right Revival
- 2007-02-14 AU AU2007214668A patent/AU2007214668B2/en active Active
- 2007-02-14 AT AT07722818T patent/ATE510014T1/de not_active IP Right Cessation
- 2007-02-14 CN CN2007800113050A patent/CN101415825B/zh active Active
- 2007-02-14 US US12/279,183 patent/US8193159B2/en active Active
- 2007-02-14 KR KR1020137020808A patent/KR101572893B1/ko not_active Expired - Fee Related
- 2007-02-14 WO PCT/EP2007/001294 patent/WO2007093409A2/en not_active Ceased
- 2007-02-14 PL PL09012826T patent/PL2135949T3/pl unknown
- 2007-02-14 EP EP07722818A patent/EP1984501B1/en not_active Not-in-force
- 2007-02-14 MX MX2011010706A patent/MX337801B/es unknown
- 2007-02-14 KR KR1020087022289A patent/KR101475865B1/ko active Active
- 2007-02-14 PT PT90128265T patent/PT2135949E/pt unknown
-
2012
- 2012-06-04 US US13/487,341 patent/US8691784B2/en active Active
-
2014
- 2014-04-06 US US14/246,134 patent/US9670491B2/en active Active
-
2017
- 2017-06-06 US US15/614,665 patent/US10273480B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526532A5 (enExample) | ||
| RU2008136907A (ru) | Нуклеиновые кислоты, связывающиеся с мср-1 | |
| CN108368509B (zh) | 改善了血中滞留性的抗il－17适体 | |
| Nunez et al. | Transient DNA occupancy of the SMC interarm space in prokaryotic condensin | |
| Ouellet et al. | Hi‐Fi SELEX: a high‐fidelity digital‐PCR based therapeutic aptamer discovery platform | |
| JP2013524792A5 (enExample) | ||
| JP2008504842A5 (enExample) | ||
| US8741558B2 (en) | Compositions, methods, and kits for identifying candidate molecules from encoded chemical libraries | |
| JP2018534329A (ja) | Ｃｘｃｒ２の阻害剤 | |
| JP2009504754A (ja) | 単環式および二環式化合物と使用法 | |
| JP2009543567A5 (enExample) | ||
| Hedayati Ch et al. | Isolation of a new ssDNA aptamer against staphylococcal enterotoxin B based on CNBr‐activated sepharose‐4B affinity chromatography | |
| JP2016517273A (ja) | Ｉｌ−６に結合するアプタマー及びｉｌ−６介在性状態の治療または診断におけるそれらの使用 | |
| CN104114714A (zh) | Gabr-a2诊断 | |
| TW201345919A (zh) | 探針、微陣列、探針群組、β地中海型貧血檢測套組、β血球蛋白基因變異檢測用套組、多態性檢測用微陣列探針對的評價方法以及基因型判別顯示程式 | |
| Zhu et al. | A detective story in drug discovery: elucidation of a screening artifact reveals polymeric carboxylic acids as potent inhibitors of RNA polymerase. | |
| KR20220059472A (ko) | Rna-표적화 리간드, 이의 조성물, 및 이의 제조 및 사용 방법 | |
| EP2367959B1 (en) | Methods for shortening incubation times in hybridization assays | |
| US10640772B2 (en) | DNA aptamers binding to molecular targeted agents and detection method of molecular targeted medicine using the same | |
| Hu et al. | Selection and identification of a DNA aptamer that mimics saxitoxin in antibody binding | |
| He et al. | Functional SELEX and Biomedical Applications of Aptamers: Beyond Molecular Recognition | |
| JP5777341B2 (ja) | Ｍｃｐ−１結合核酸およびその使用 | |
| Schirle et al. | Selective inhibition of ADAR2-catalyzed editing of the serotonin 2c receptor pre-mRNA by a helix-threading peptide | |
| WO2013078684A1 (zh) | 一种组装双亲基因组的方法 | |
| Kouhpayeh et al. | Development of α4 integrin DNA aptamer as a potential therapeutic tool for multiple sclerosis |